Trendlines Group Ltd. · SGX:42T
Trendlines — The Trendlines Group — Investor Presentation (December 2016)
19 slides from Trendlines's investor presentation, December 2016
Slide 1: Creating & Developing Companies To Improve the Human Condition
Creating & Developing Companies To Improve the Human Condition Post-IPO Update Steve Rhodes, Chairman & CEO Todd Dollinger, Chairman & CEO December 2016
Slide 2: IPO Singapore (26 November 2015)
IPO Singapore (26 November 2015) Successful offering, reasonable valuation • Placement of 75.8 million shares at S$0.33 • Gross proceeds raised of S$25 million • Total capital raised approximately S$38.7 million (includes S$13.7 million from pre-IPO investors) • B.Braun Melsungen entered as cornerst
Slide 3: Renewal of OCS License(s)
Renewal of OCS License(s) • Renewed Trendlines Medical license • Trendlines received OCS (Office of the Chief Scientist) approval to operate Trendlines Agtech and Trendlines Medical under a single license in our headquarters facility • Today operate both incubators under a single license in a single
Slide 4: Corporate Financial Developments
Corporate Financial Developments • Trendlines completed exit of portfolio company E.T.View Medical for net proceeds of US$ 3.6 million • Trendlines received US$ 0.9 million dividend from the Most Valuable Portfolio Company in Q3 2016 – increased cash balance, but no impact on earnings • More than do
Slide 5: Earnings Results as of 30 September 2016
Earnings Results as of 30 September 2016 • Q3 2016 vs Q3 2015 • Total income was US$ 4.1 million in Q3 2016, compared to loss of US$ 0.2 million in Q3 2015 • Net income totaled US$ 1.6 million in Q3 2016 vs loss of US$ 3.4 million in Q3 2015 • First 9 months of 2016 vs first 9 months of 2015 • Total
Slide 6: Major Corporate Partnerships: B. Braun Melsungen AG
Major Corporate Partnerships: B. Braun Melsungen AG • B. Braun is one of the world’s largest privately owned medical device distributor with global sales of € 6.12 billion • B. Braun invested S$ 7.1 million as cornerstone investor in listing of Trendlines on the SGX • B. Braun signed definitive agre
Slide 7: Major Corporate Partnerships: Bayer AG
Major Corporate Partnerships: Bayer AG • Bayer AG is a public company (market cap € 73.5 billion) with global sales of € 46.3 billion • Bayer Crop Science announced a partnership with Trendlines to invest in agricultural technologies through the establishment of the Bayer Trendlines Ag Innovation Fu
Slide 8: Major Corporate Partnerships: Japanese Medical Device MNC
Major Corporate Partnerships: Japanese Medical Device MNC • Trendlines Labs partners with major multinational medical device corporation (MNC) headquartered in Japan. • Japanese MNC signed an agreement with Trendlines Labs to collaborate on clinical opportunities in agreed fields • Trendlines Labs t
Slide 9: Major Corporate Partnerships: U.S. Medical Device MNC
Major Corporate Partnerships: U.S. Medical Device MNC • Trendlines Labs partners with major U.S. multinational medical device manufacturer • One product successfully introduced to market (LithoVue™ ureteroscope) • One project completed proof of concept • One investigation (Endo division) • Additiona
Slide 10: Expansion of Operations into New Markets
Expansion of Operations into New Markets • Trendlines establishes Trendlines Medical Singapore, the first medical incubator established by an Israeli company in Singapore and Trendlines’ first incubator outside of Israel • Eric Loh appointed CEO, Trendlines Medical Singapore • B. Braun signs definit
Slide 11: Select Trendlines Medical Portfolio Company Milestones
Select Trendlines Medical Portfolio Company Milestones • ApiFix exceeds 100-patient milestone and Eran Feldhay named CEO • Gordian Surgical receives CE Mark • CoreBone receives CE Mark and ISO • OrthoSpin starts FIM trials • LapSpace performs ~200 cases; sells approximately 150 devices • Leviticus C
Slide 12: Select Trendlines AgTech Portfolio Company Milestones
Select Trendlines AgTech Portfolio Company Milestones • EdenShield receives US patent for its nontoxic pest control solution, reaches sales of ~ US$ 220,000 • ViAqua achieves excellent test results in US & Thailand • AquiNovo is in negotiation with a strategic partner • BioFishency reaches sales of
Slide 13: Follow-on funding for Portfolio companies
Follow-on funding for Portfolio companies • Magdent • Breezy • EdenShield • GreenSpense • Hargol • Gordian • Leviticus • ApiFix • Saturas • ProArc • CoreBone • Arcuro* • VivoText • OMEQ Medical • Liola • Vensica* • Advanced Memtech *First round 13
Slide 14: Portfolio Expansion: 8 New Companies
Portfolio Expansion: 8 New Companies Tandem Technologies Zeev Implants OB Smart Hargol FoodTech AquiNovo InPlant Technologies CorAlert MetoMotion 14
Slide 15: Trendlines Labs
Trendlines Labs • Two development programs with new strategic partners • Three new strategic, revenue-producing agreements • Two Trendlines Labs’ technologies entering commercialization stage: ‒ EUS FNA Biopsy Needles (incubator company in process) ‒ Stress Urinary Incontinence (SIIRD with Singapore
Slide 16: Keeping Our Promises to Investors
Keeping Our Promises to Investors Since our listing in November 2015 Our Goals What We Did 1. Renew licenses from Israeli gov’t. Renewed one license and merged second into it 2. Start new companies Started 9 new companies 3. Establish new incubator Established Trendlines Medical Singapore 4. Grow Tr
Slide 17: Building a Strong Investor Base
Building a Strong Investor Base • Judith Kleinman named Director of Investor Relations & Corporate Communications ‒ 10 years investment banking: analyst & institutional sales ‒ 15 years investor relations: consultant & in-house • Active IR schedule: Asia & North America ‒ Conferences ‒ Non-deal road
Slide 18: Creating & Developing Companies To Improve the Human Condition
Creating & Developing Companies To Improve the Human Condition Todd Dollinger, Chairman & CEO Steve Rhodes, Chairman & CEO +972.72.260.7000 | www.trendlines.com Judith Kleinman, Director Investor Relations & Corporate Communications judith@trendlines.com 18 December 2016
Slide 19: Issuer/Manager THE TRENDLINES GROUP LTD.
Issuer/Manager THE TRENDLINES GROUP LTD. Securities THE TRENDLINES GROUP LTD. – IL0011328858 – 42T Stapled Security No Announcement Title General Announcement Date & Time of Broadcast 21 Dec 2016 19:59:51 Status New Announcement Subtitle One-Year Post-IPO Presentation Announcement Reference SG161221
The Trendlines Group — Investor Presentation (December 2016) on 6ix